Eficacia del Ulipristal como tratamiento en la reducción del tamaño de los miomas

Abstract

Uterine fibroids, also known as leiomyomas, are benign neoplasms arising from smooth muscle cells in the myometrium, affecting approximately 40% of women of reproductive age. Their growth is stimulated mainly by estrogens and progesterone. Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), has shown efficacy in reducing the size of fibroids and improving symptoms such as menstrual bleeding and pelvic pain. The literature review reveals that, although UPA is presented as a promising alternative to surgical treatment of uterine fibroids, close monitoring of liver function is essential to ensure patient safety. Evidence suggests the importance of estrogens and progesterone in the pathophysiology of fibroids, making SPRMs an effective therapeutic option. However, the recent discontinuation of UPA highlights the need for further research to evaluate its hepatic safety. Thus, UPA remains a viable and effective option for patients with symptomatic uterine fibroids, provided that adequate surveillance is performed and each case is considered on an individual basis.